190 related articles for article (PubMed ID: 31274552)
1. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.
Kertels O; Mihovilovic MI; Linsenmann T; Kessler AF; Tran-Gia J; Kircher M; Brumberg J; Monoranu CM; Samnick S; Ernestus RI; Löhr M; Meyer PT; Lapa C
Clin Nucl Med; 2019 Sep; 44(9):695-701. PubMed ID: 31274552
[TBL] [Abstract][Full Text] [Related]
2. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
[TBL] [Abstract][Full Text] [Related]
4. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
[TBL] [Abstract][Full Text] [Related]
5. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
6. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
7. Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
Kebir S; Rauschenbach L; Gielen GH; Schäfer N; Tzaridis T; Scheffler B; Giordano FA; Lazaridis L; Herrlinger U; Glas M
J Clin Neurosci; 2018 Jul; 53():255-258. PubMed ID: 29754968
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[
Harat M; Małkowski B; Roszkowski K
Radiat Oncol; 2019 Mar; 14(1):37. PubMed ID: 30832691
[TBL] [Abstract][Full Text] [Related]
9. [
Koh ES; Gan HK; Senko C; Francis RJ; Ebert M; Lee ST; Lau E; Khasraw M; Nowak AK; Bailey DL; Moffat BA; Fitt G; Hicks RJ; Coffey R; Verhaak R; Walsh KM; Barnes EH; De Abreu Lourenco R; Rosenthal M; Adda L; Foroudi F; Lasocki A; Moore A; Thomas PA; Roach P; Back M; Leonard R; Scott AM
BMJ Open; 2023 Aug; 13(8):e071327. PubMed ID: 37541751
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
[TBL] [Abstract][Full Text] [Related]
11. Can Early Postoperative O-(2-
Buchmann N; Gempt J; Ryang YM; Pyka T; Kirschke JS; Meyer B; Ringel F
World Neurosurg; 2019 Jan; 121():e467-e474. PubMed ID: 30267942
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
13. Potential for differentiation of glioma recurrence from radionecrosis using integrated
Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
[TBL] [Abstract][Full Text] [Related]
15. O-(2-(
Mihovilovic MI; Kertels O; Hänscheid H; Löhr M; Monoranu CM; Kleinlein I; Samnick S; Kessler AF; Linsenmann T; Ernestus RI; Buck AK; Lapa C
J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):238-239. PubMed ID: 29705720
[No Abstract] [Full Text] [Related]
16. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
[TBL] [Abstract][Full Text] [Related]
17. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
[TBL] [Abstract][Full Text] [Related]
18. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.
Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ
J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742
[TBL] [Abstract][Full Text] [Related]
19. The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents.
Dunkl V; Cleff C; Stoffels G; Judov N; Sarikaya-Seiwert S; Law I; Bøgeskov L; Nysom K; Andersen SB; Steiger HJ; Fink GR; Reifenberger G; Shah NJ; Coenen HH; Langen KJ; Galldiks N
J Nucl Med; 2015 Jan; 56(1):88-92. PubMed ID: 25525183
[TBL] [Abstract][Full Text] [Related]
20. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
